PhRMA Statement on Clinical Trials, Research Collaborations and Washington Post Article

Phrma: 11/26/12

Washington, D.C. (November 26, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today:

The Washington Post story ‘Can Drug Research Still Be Trusted?’ presents a one-sided view of the critically important scientific endeavors that explore and ultimately discover and produce life-saving innovative medicines. The article is based upon the unfounded assumption that any industry funding of clinical research inherently leads to a conflict of interest and thus bias in results.  It presumes such inherent bias does not exist when funding is provided by other sources, such as government or academic institutions.

“The narrow focus on industry funding as the sole source of potential conflicts of interest is unfortunate and unwarranted, and tarnishes the important role that the biopharmaceutical industry plays in driving innovation and bringing treatments forward to address unmet medical needs. While potential for bias in research may exist regardless of the source of funding, all researchers whether in academia or industry should not be presumed to be anything but devoted to generating the best scientific findings. For example, academic researchers are rewarded based on publishing in reputable scientific journals such as the New England Journal of Medicine and National Institutes of Health (NIH) grants are awarded based on publishing track records among other criteria.  Experts are sought out by top tier academic institutions, industry and regulators based on their body of work. Read More